Previous Close | 239.77 |
Open | 240.71 |
Bid | 242.15 x 1400 |
Ask | 242.79 x 1000 |
Day's Range | 239.50 - 243.50 |
52 Week Range | 181.36 - 349.84 |
Volume | |
Avg. Volume | 622,109 |
Market Cap | 12.282B |
Beta (5Y Monthly) | 1.29 |
PE Ratio (TTM) | 33.80 |
EPS (TTM) | 7.20 |
Earnings Date | Feb 14, 2023 - Feb 20, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 270.17 |
The broad-based demand and meaningful price increases in the RMS business particularly in North America are expected to have contributed to Charles River's (CRL) top line in Q4.
WILMINGTON, Mass., January 30, 2023--Charles River Laboratories Acquires SAMDI Tech
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of